Clik here to view.
Salix inventory snafu sinks deal with Allergan
(Reuters) — Salix Pharmaceuticals (NSDQ:SLXP) slashed its full-year forecast yesterday and said inventory for its key drugs piled up, an issue that people familiar with the matter said dissuaded...
View ArticleClik here to view.
Report: Actavis may buy Allergan for at least $60 billion
(Reuters) – Merger talks between Allergan (NYSE:AGN) and white knight Actavis (ACT) are focused on narrowing a gap of about $3 billion between what has been offered and what is wanted, Bloomberg...
View ArticleClik here to view.
Capricor buys Medtronic peptide patent rights
Capricor Therapeutics said it acquired Medtronic‘s (NYSE:MDT) patent rights for the formulation and delivery of natriuretic peptides. Capricor said it plans to use the patents for its clinical program...
View ArticleClik here to view.
Source: Allergan near $66B buyout to escape Valeant, Ackman
(Reuters) — Allergan (NYSE:AGN) is close to a buyout deal worth up to $65.5 billion by Actavis (NYSE:ACT) that could end months of pursuit by Canada’s Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and...
View ArticleClik here to view.
UPDATE: Actavis trumps Valeant with $66B offer for Allergan
Actavis (NYSE:ACT) trumped by $12 billion the hostile takeover bid for Allergan (NYSE:AGN) by Canada’s Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and William Ackman’s Pershing Square Capital...
View ArticleClik here to view.
Pfizer offers $15 billion for Hospira
(Reuters) — Pfizer (NYSE:PFE) said it would buy Hospira (NYSE:HSP) for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer is known for...
View ArticleClik here to view.
Bayer aims to boost drugs sales, margins over next 3 years
(Reuters) — Bayer (ETR:BAYN) aims to increase sales of its main healthcare division by an annual 6% until 2017, with growth prospects for new drugs such as stroke prevention pill Xarelto boosting...
View ArticleClik here to view.
Another FDA warning letter for Hospira
(Reuters) — Hospira (NYSE:HSP), which agreed in February to be bought by Pfizer (NYSE:PFE), said the FDA sent it another warning letter detailing violations in standard drug manufacturing practices at...
View ArticleClik here to view.
Baxter looks to growth post-Baxalta spinout
Baxter (NYSE:BAX) said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta. "The spin-off provides us with flexibility to bring...
View ArticleClik here to view.
Baxalta wants Shire to boost $30B takeover bid
(Reuters) — Baxalta (NYSE:BXLT), the spinout of Baxter‘s (NYSE:BAX) biopharmaceuticals division, wants Shire (NSDQ:SHPGY) to improve on its $30 billion bid significantly before it will engage in...
View ArticleClik here to view.
Pfizer closes $15B Hospira takeover
Pfizer (NYSE:PFE) yesterday closed its $15 billion acquisition of Hospira, its largest-ever buyout, expanding its portfolio of generic injectable drugs and copies of biotech medicines. Hospira makes...
View ArticleClik here to view.
Exit interview: Stephen Ubl on moving on from AdvaMed
Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech’s main man in Washington, D.C., sat down with MassDevice.com publisher Brian Johnson to reflect on...
View ArticleClik here to view.
Pfizer, Allergan in talks on merger
(Reuters) — Allergan (NYSE: AGN) and Pfizer (NYSE:PFE) today confirmed that they’re in preliminary, friendly talks on a potential merger, a deal that would create the world’s largest drugmaker. Both...
View ArticleClik here to view.
Short seller Citron backs off Valeant claims
(Reuters) — Influential short-selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) yesterday, as many investors had anticipated, giving the...
View ArticleClik here to view.
Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or...
View ArticleClik here to view.
Drug pricing scandal: Pharma’s loss is medtech’s gain
The scandal swirling round drug pricing is pushing investors to medical device stocks in lieu of pharmaceutical and biotech plays. Edwards Lifesciences (NYSE:EW), Boston Scientific (NYSE:BSX) and...
View ArticleClik here to view.
Alimera surges on buyout rumors
(Reuters) — Alimera Sciences (NSDQ:ALIM), an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with...
View ArticleClik here to view.
Insulet inks deal for Lilly’s Humalog concentrated insulin
Insulet (NSDQ:PODD) said yesterday that it inked a deal with Eli Lilly (NYSE:LLY) to develop a version of its flagship OmniPod device that uses a concentrated insulin made by the pharma giant. Lilly’s...
View ArticleClik here to view.
Report: Pfizer mulls sale of Hospira infusion pump biz
Pfizer (NYSE:PFE) is reportedly mulling a sale of the infusion pump business it acquired along with Hospira last year, aiming to focus on its core branded pharmaceuticals business. Hospira makes...
View ArticleClik here to view.
MEPS Real-Time expands staff, headquarters
RFID inventory management company MEPS Real-Time said it is adding to its sales, marketing, product management and engineering team, as well as expanding its Carlsbad, Calif.-based headquarters nearly...
View Article